Oral and injectable antiquaguane in the prevention of thromboembolic events

Comparison of the effects of oral and injectable antiquaguane in the prevention of thromboembolic events in patients with gynecological cancers who underwent surgery.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231026059867N1

Enrollment

100

Registered

2023-11-08

Start date

2023-12-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Thrombosis. Condition 2: Pulmonary embolism. Acute embolism and thrombosis of deep veins of lower extremity Pulmonary embolism

Interventions

Intervention 1: Intervention group: Receiving the oral anticoagulant apixaban tablets made in Elixir Pharmaceutical Company, 2.5 mg twice a day for 3 months. Intervention 2: Intervention group: Receiv

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: People who have undergone surgery for gynecological cancers Candidate to receive oral or injectable anticoagulants

Exclusion criteria

Exclusion criteria: Lack of consent to continue participating in the study History of thromboembolic events

Design outcomes

Primary

Measure	Time frame
Venous thrombosis. Timepoint: 2 and 6 and 12 weeks after starting treatment. Method of measurement: Physical examination and history taking.;Pulmonary embolism. Timepoint: 2 and 6 and 12 weeks after starting treatment. Method of measurement: Physical examination and history taking.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Anaie

Esfahan University of Medical Sciences

mjp_368@yahoo.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026